Linked Life Data

12384535

Source:http://linkedlifedata.com/resource/pubmed/id/12384535

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
20
pubmed:dateCreated
2002-10-17
pubmed:abstractText
We investigated the biodistribution of (88)Y/(111)In-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin and therapy with (90)Y-labeled DOTA-biotin in tumor-bearing mice after B3-streptavidin antibody conjugate (B3-SA) pretargeting. B3 antibody, recognizing Lewis(y) antigen, was conjugated to streptavidin (B3-SA). For pretargeting, 400 micro g of the B3-SA was injected i.v. into mice bearing A431 tumor xenografts. After tumor localization of B3-SA, 100 micro g of synthetic clearing agent was injected i.v. to clear the unbound B3-SA from the circulation. Four h later, 1 micro g of radiolabeled DOTA-biotin was injected i.v. Radioimmunotherapy was performed with doses of 9.25 to 37 MBq of (90)Y-labeled DOTA-biotin. As a result, radiolabeled DOTA-biotin cleared rapidly. All of the normal tissues had <2.6% of the injected dose per gram, whereas tumor uptake reached approximately 15% ID/g. The total tumor uptake of radioactivity remained similar for 96 h or longer. In the first study, the median survival of the control group was 8 days, whereas it increased to >163 days in the 37 MBq (90)Y group (P < 0.005). In a second therapy group, 7 of 10 mice receiving 37 MBq of (90)Y and B3-SA were cured, and remained healthy for >180 days after therapy, compared with control groups, with </=29.2 days mean survival time (P < 0.001). Tumor pretargeting with B3-SA and radiolabeled DOTA-biotin has shown favorable, specific, and fast targeting that has resulted in good tumor responses and, thus, serves as a rationale for human studies with the B3-SA pretargeting approach.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0008-5472
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
62
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5755-60
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed-meshheading:12384535-Animals, pubmed-meshheading:12384535-Antibodies, Monoclonal, pubmed-meshheading:12384535-Biotin, pubmed-meshheading:12384535-Carcinoma, Squamous Cell, pubmed-meshheading:12384535-Drug Synergism, pubmed-meshheading:12384535-Female, pubmed-meshheading:12384535-Humans, pubmed-meshheading:12384535-Immunoconjugates, pubmed-meshheading:12384535-Indium Radioisotopes, pubmed-meshheading:12384535-Mice, pubmed-meshheading:12384535-Mice, Nude, pubmed-meshheading:12384535-Organometallic Compounds, pubmed-meshheading:12384535-Radioimmunotherapy, pubmed-meshheading:12384535-Radiopharmaceuticals, pubmed-meshheading:12384535-Streptavidin, pubmed-meshheading:12384535-Tissue Distribution, pubmed-meshheading:12384535-Xenograft Model Antitumor Assays, pubmed-meshheading:12384535-Ytterbium
pubmed:year
2002
pubmed:articleTitle
Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
pubmed:affiliation
Nuclear Medicine Department of the Warren G. Magnuson Clinical Center, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.
pubmed:publicationType
Journal Article